Market Report, 207 Pages
April 2024
CAR-T industry funding isn’t only gaining traction, it is surging. At first, the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti have reached the marketplace and created a funding boom. CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine.
Worldwide, more than 170 companies are engaged in developing CAR-T products and therapies. These CAR-T therapy companies have developed nearly 970 early and late-stage therapies. These companies have also signed an incredible 98 collaboration deals to progress the development of various CAR-T product candidates. Of these, 33 collaboration deals have disclosed their financial terms, which account for a total of $21.7 billion in transactions. If an estimate is made for the collaboration deals that have not disclosed their terms, the total value of these 98 collaboration deals would be in the range of an astonishing $63 billion.
Over the past decade, CAR-T companies have also attracted venture capital investments worth an incredible $6.7 billion, enabling these CAR-T companies to invest in their infrastructure and product pipelines.
During the same period, CAR-T companies raised an impressive $5.757 billion through IPO funding to strengthen their technology platforms, clinical trial programs, and corporate efforts.
Within this nascent industry, with over 417,801 patent records and 4,024 granted patents, large pharma has increasingly been seeking to enter the CAR-T field by licensing rights from existing patent owners. Thus, the total value of CAR-T licensing deals over the past decade account for another $3.9 billion in transactions and this total is expected to expand substantially in the coming decade.
Among the various financing types analyzed in this report—which include CAR-T industry IPOs, licensing deals, collaborations, strategic partnerships, and M&A deals—M&A deals constitute the largest financial percentage, accounting for an astounding $95.9 billion over the past decade.
Growth of the Nascent CAR-T Cell Therapy Industry
For the nascent CAR-T industry, it is a phenomenal achievement to raise more than $128.25 billion through these various deals that have reported their financial terms, including CAR-T industry IPOs, licensing deals, collaboration deals, and M&A deals. Additionally, 59 of 84 CAR-T licensing deals, 65 of the 98 CAR-T collaboration deals, and 11 of the 27 CAR-T industry M&A deals did not disclose the value of their transactions.
Thus, if an approximate estimate is calculated for all deals of undisclosed values, the total value would be a staggering $240 billion.
At present, six CAR-T therapies have been approved by U.S. FDA, including:
- Tisagenlecleucel-T (Kymriah)
- Axicabtagene ciloleucel (Yescarta)
- Brexucabtagene autoleucel (Tecartus)
- Lisocabtagene maraleucel (Breyanzi)
- Idecabtagene vicleucel (Abecma)
- Ciltacabtagene autoleucel (Carvykte)
Many of the CAR-T therapies above have been approved by other regulatory agencies, most commonly for use within the EU. CAR-T therapies have reached commercialization in other regions as well, such as Relma-cel’s (Relmacabtagene) and Yikaida’s (Axicabtagene ciloleucel) approval from the NMPA in China, Ebvallo’s (tabelecleucel) approval from the European Commission, Actaly-cel’s (Actalycabtagene autoleucel) in India, and Fucaso’s (Equecabtagene autoleucel) approval in China, for example. Of course, this list is not exhaustive and CAR-T approvals are accelerating on a global scale.
According to ClinicalTrials.gov, there are also an incredible 706 CAR-T programs that are in clinical phases of development.
To summarize, there have been hundreds of billions of dollars in financial transactions completed by CAR-T companies in recent years. Ranging from small start-ups to billion-dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.
CAR-T Market Overview
To track these industry events, BioInformant released this 207 page CAR-T market funding report. It summarizes all types of investments flowing into CAR-T companies worldwide, including financing rounds, IPOs, M&A transactions, co-development agreements, and strategic partnerships. Additionally, it profiles 78 leading competitors who have been involved with these CAR-T industry funding events.
It features the following information for the CAR-T cell therapy industry:
- Financing Rounds
- IPOs
- Asset Agreements
- Strategic Partnerships
- Co-Development Agreements
- M&A Transactions
- Companies Profiles for CAR-T Market Competitors
Use it to:
- Quantify CAR-T industry investments
- Identify well-capitalized companies
- Scout potential partnerships and alliances
- Understand partnerships and co-development programs for CAR-T technologies
- Identify M&A activity within the CAR-T industry
TABLE OF CONTENTS: CAR-T Funding Report – Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2024
This research was originally compiled for our internal use, but many of BioInformant’s clients were requesting access to it.
Would you benefit from accessing all known CAR-T cell therapy funding events worldwide? If so, you can claim this report below and your order will be available for immediate download with printing rights allowed.
Of course, your investment is backed by BioInformant’s 60-Day Money Back Guarantee.
About BioInformant
With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 17+ years of experience. As the first and only market research firm to specialize in the cell therapy industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Headquartered near Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), U.S. FDA, Maryland Biotech Corridor, and policy makers on Capitol Hill. Serving all-star clients that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in cell therapy industry data. For more information, read Client Testimonials here.